AML Regression by Vascular Disruption with OXi4503 and Anti-Angiogenesis with Bevacizumab.

Gerard J. Madlambayan(University of Rochester), Christopher R. Cogle(University of Florida), Marda Jorgensen(University of Florida), Amy Meacham(University of Florida), Edward W. Scott(University of Florida), Dietmar W. Siemann(University of Florida Health), Saad Mir, Koji Hosaka(Institute for Stem Cell Biology and Regenerative Medicine)
Blood
November 20, 2009
Cited by 0


Related Papers